- Home
- ATNI vs DSGN Comparison
ATNI vs DSGN Comparison
Compare ATNI & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNI
- DSGN
- Stock Information
- Founded
- ATNI 1987
- DSGN 2017
- Country
- ATNI United States
- DSGN United States
- Employees
- ATNI N/A
- DSGN 54
- Industry
- ATNI Telecommunications Equipment
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- ATNI Telecommunications
- DSGN Health Care
- Exchange
- ATNI Nasdaq
- DSGN Nasdaq
- Market Cap
- ATNI 337.8M
- DSGN 353.9M
- IPO Year
- ATNI 1991
- DSGN 2021
- Fundamental
- Price
- ATNI $17.55
- DSGN $6.39
- Analyst Decision
- ATNI Strong Buy
- DSGN Hold
- Analyst Count
- ATNI 2
- DSGN 3
- Target Price
- ATNI $31.00
- DSGN $7.00
- AVG Volume (30 Days)
- ATNI 84.7K
- DSGN 156.0K
- Earning Date
- ATNI 10-29-2024
- DSGN 11-07-2024
- Dividend Yield
- ATNI 5.47%
- DSGN N/A
- EPS Growth
- ATNI N/A
- DSGN N/A
- EPS
- ATNI N/A
- DSGN N/A
- Revenue
- ATNI $747,493,000.00
- DSGN N/A
- Revenue This Year
- ATNI N/A
- DSGN N/A
- Revenue Next Year
- ATNI $1.20
- DSGN N/A
- P/E Ratio
- ATNI N/A
- DSGN N/A
- Revenue Growth
- ATNI N/A
- DSGN N/A
- 52 Week Low
- ATNI $17.31
- DSGN $2.25
- 52 Week High
- ATNI $39.88
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- ATNI 31.99
- DSGN 51.81
- Support Level
- ATNI $17.39
- DSGN $5.16
- Resistance Level
- ATNI $18.06
- DSGN $6.43
- Average True Range (ATR)
- ATNI 0.65
- DSGN 0.50
- MACD
- ATNI 0.15
- DSGN -0.03
- Stochastic Oscillator
- ATNI 20.10
- DSGN 56.08
About ATNI ATN International Inc.
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise US Telecom and International Telecom. The company earns revenue from its telecommunication services.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.